ProCE Banner Activity

SGLT2 Inhibitors Reduce CV Mortality, Heart Failure Hospitalizations in Patients With Heart Failure: Systematic Review and Meta-analysis

Slideset Download
Conference Coverage
In meta-analysis of 15 randomized, placebo-controlled clinical trials, SGLT2 inhibitors reduced risk of all-cause and CV mortality and risk of composite heart failure endpoint in key patient subgroups.

Released: July 01, 2021

Expiration: June 30, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from